The severity of adverse reactions to Binimetinib(Mektovi) varies from individual to individual, but in general, most adverse reactions are manageable and not too severe, but some may be serious and require close attention and management.

Are the adverse effects of Binimetinib(Mektovi) serious?

Common adverse effects of Binimetinib (incidence ≥25%) include fatigue, nausea, diarrhoea, vomiting, and abdominal pain. These reactions are usually mild to moderate and can be controlled and alleviated with proper medical management and adjustment of drug dosage.

Binimetinib may also cause some more serious adverse effects, such as the possibility that Binimetinib may cause cardiomyopathy, a condition that affects the heart muscle and may lead to decreased heart function. Binimetinib may also increase the risk of venous thromboembolism, such as deep vein thrombosis and pulmonary embolism. These serious adverse effects require close monitoring and may require appropriate treatment, such as drug dose adjustment, drug withdrawal, or specific medical intervention.

Before starting Binimetinib, the doctor will conduct a thorough evaluation of the patient, including an assessment of the patient's potential cardiovascular risks and other health problems. During treatment, doctors also regularly monitor the patient's health and adjust the treatment plan as needed.

How can Binimetinib reduce the incidence of adverse reactions when used?

When Binimetinib is used, in order to reduce the incidence of adverse reactions, the following measures can be taken:

1. Correct medication

Patients are advised to take their medications exactly as recommended by their doctor, including dosage, timing and frequency of medication. The recommended dose of Binimetinib is 45 mg twice a day, with an interval of about 12 hours, and patients are advised not to increase or decrease the dose on their own, nor to stop or change the dose at will. If you forget to take your medication, do not make up the dose within 6 hours before your next dose and continue with your next dose as planned.

2. Monitoring and evaluation

Patients need to monitor cardiac function by echocardiography or MUGA scan to assess ejection fraction before starting treatment, 1 month after starting treatment, and every 2 to 3 months during treatment. Patients with cardiovascular risk factors should be closely monitored for cardiovascular status. Monitor liver function and other relevant indicators regularly so that possible adverse reactions such as hepatotoxicity can be detected and treated in a timely manner.

Through the implementation of the above measures, the incidence of adverse reactions of Binimetinib can be effectively reduced, the treatment effect and quality of life of patients can be improved, and patients should also maintain a positive attitude and good living habits, and cooperate with doctors to jointly cope with the challenges of the disease.